Jpmorgan Chase & CO Alpha Tau Medical Ltd. Transaction History

Jpmorgan Chase & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$2.98 - $4.24 $1,418 - $2,018	476 Added 1.21%	39,656 $150,000
Q2 2023 Aug 11, 2023	SELL	$2.76 - $4.72 $53,535 - $91,553	-19,397 Reduced 33.11%	39,180 $171,000
Q1 2023 May 11, 2023	SELL	$2.78 - $4.83 $2,143 - $3,723	-771 Reduced 1.3%	58,577 $168,000
Q4 2022 Feb 13, 2023	SELL	$3.05 - $5.49 $48,092 - $86,566	-15,768 Reduced 20.99%	59,348 $189,000
Q3 2022 Nov 14, 2022	SELL	$0.65 - $11.0 $1,476 - $24,981	-2,271 Reduced 2.93%	75,116 $439,000
Q2 2022 Aug 11, 2022	BUY	$5.19 - $12.67 $401,638 - $980,493	77,387 New	77,387 $697,000

1.36M

Ticker DRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,011,296
Market Cap $213M
Description
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast canc...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.